

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

INSIDE INFORMATION

ESTABLISHMENT OF NEW FACILITY IN DUNDALK, IRELAND

This announcement is made by WuXi Biologics (Cayman) Inc. (the “**Company**”, together with its subsidiaries the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Company has entered into discussions with the Government of the Republic of Ireland in relation to the construction of a new manufacturing facility on the greenfield site of the Industrial Development Authority of Ireland in Mullagharlin, Dundalk, County Louth, Republic of Ireland (the “**New Facility**”). Under the Company’s preliminary development plan, the New Facility may involve a total investment amount of approximately €325 million (equivalent to approximately HKD\$3,092 million) over the next five years, and it is expected that the New Facility will house multiple disposable bioreactors for commercial biomanufacturing with a total of 48,000L fed-batch bioreactor capacity and 6,000L perfusion bioreactor capacity, making the New Facility one of the world’s largest using disposable bioreactors when the New Facility enters into GMP run.

The New Facility is the Company's first facility to be constructed outside China, which is designed to run continuous bioprocessing, a next generation manufacturing technology to be first implemented globally. The New Facility will further expand the Group's capabilities and capacities of commercial manufacturing and will strengthen its global integrated solution platform under the "Follow-the-Molecule" strategy. The initiation of the Group's first site outside China will enable local companies to expedite biologics development in Europe. By expanding the Group's global biomanufacturing network, it will help to ensure that biologics are manufactured by the Group to the highest quality with a robust supply chain to benefit patients worldwide.

The Board is of the view that the construction of the New Facility, which is intended to be for the Group's own use in its ordinary and usual course of business, is in the interests of the Company as well as its shareholders as a whole. Further announcement(s) will be made by the Company in accordance with the applicable requirements under the Listing Rules as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, April 30, 2018

As of the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Mr. Edward Hu, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Wo Felix Fong as independent non-executive Directors.

** For identification purpose only*